1639-Overcoming PARP Inhibitor Resistance in TNBC
This paper describe how PARP inhibitors, while effective at treating BRCA-associated triple-negative breast cancer (TNBC), inadvertently trigger an immunosuppressive tumor microenvironment dominated by macrophages. High-dimensional profiling reveals that these tumors are heavily infiltrated by macrophages and T cells, yet the treatment causes metabolic reprogramming that enhances the pro-tumor characteristics of these myeloid cells. Specifically, the research identifies that PARP inhibition increases the expression of CSF1R and PD-L1, which contributes to drug resistance and transitory…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.